Omada Health provides chronic care that works. Through a focus on compassionate intelligence, our human-led care team provides expert guidance and one-on-one support to help members achieve personalized goals - that members are grateful for. ⭐ Omada Health coaches and specialists sent over 3.6 million messages to members in a single year. ⭐ Learn more: https://lnkd.in/e59pJKNY
Are you concerned about weight regain in your population after GLP-1 discontinuation due to cost, access issues, or other barriers? According to a recent Omada Health analysis, the support provided by Omada Enhanced GLP-1 Care Track helped those who stopped using GLP-1s maintain their weight 16 weeks following discontinuation. Learn more about how the multifaceted Omada’s platform can support your population taking GLP-1s: https://lnkd.in/eJier2nK
We know that people want access to GLP-1s for weight loss, but what type of support are they looking for? And how can employers, PBMs, and health plans provide support to their members to help improve outcomes while taking, or discontinuing, these medications? Omada Health’s Enhanced GLP-1 Care Track (ECT) provides this important, and desired, personalized support. According to recent insights from our ANSWERS initiative, members who opted into this program saw higher engagement with our program, increased self confidence, and experienced early indicators of healthy weight loss than members with similar eligibility criteria and received Omada’s standard care Learn more about the success members are seeing in a recent whitepaper: https://lnkd.in/dUB8U8Te
🚀 Big news! We’re excited to share findings from our Enhanced GLP-1 Care Track members who recently discontinued GLP-1s. On average, participating members experienced virtually no weight gain (-0.1%) four months after discontinuing a GLP-1, compared to an estimated average of 6-7% weight gain from clinical trial data. Read the full press release here: https://lnkd.in/erT8fpT4
How exactly do we evaluate whether virtual healthcare is delivering on its promise? We’re committed to using validated metrics to evaluate clinical outcomes, and we’re always excited to share our success with customers and prospects. ⭐ We’re proud that not only do our cardiometabolic programs improve clinical outcomes within recommended ranges over time, but we employ different study designs to evaluate our programs- including randomized controlled trials and analyses of real-world data. ⭐ Learn more about how we’re evaluating our programs’ value with the American Medical Association’s Return on Health framework: https://lnkd.in/eWUY3hCG
There’s a lot going on at the moment… with our Omada Cares initiative! Our employee volunteer program dedicated to addressing health disparities in communities has helped make a great impact! Last year Omadans collectively contributed: ⚡Over 700 hours volunteering ⚡236 pounds of food donated ⚡26 organizations served We’re looking forward to continuing to make an impact on our community.
💪 Building self-efficacy, or belief in one’s own ability to accomplish a goal, is crucial for long-term success in weight management. Our findings show that participants in a specifically designed GLP-1 program express increased confidence in their ability to lose weight . Want to learn more about how to set the stage for long-term weight health? Check out insights from our ANSWERS initiative: https://lnkd.in/et_kCT7J
GLP-1s have seen unprecedented demand for weight loss treatment in the U.S., but what’s to come globally? Omada Co-Founder and CEO Sean Duffy reflects on the U.S. experience in managing the rise of GLP-1s, and offers five key takeaways as global expansion draws near. What other lessons would you add? Share in the comments.
Curious about the impact AI may have on the diagnostic process in digital health? If so, this is for you. Last year, the National Academies of Sciences, Engineering, and Medicine’s Forum on Advancing Diagnostic Excellence hosted a workshop to discuss the role of AI and digital health technologies throughout the diagnostic process and the impact on the patient experience. Our Chief Privacy and Regulatory Officer Lucia Savage joined the discussions, which highlighted how clinicians may look to safely leverage AI and digital health tools going forward to understand symptoms, improve information gathering and patient–clinician communication, and support clinical decision making. Check out the experts’ perspectives on the matter:
American businesswoman Mary Kay Ash once said, "A company is only as good as the people it keeps.” At Omada, CHRO Nancy Vitale is helping foster a culture that helps attract and keep its people. ❓How does she do it and what led her to Omada? ❓ Check out her engaging interview on the 'Built by People' podcast now! In the episode, Nancy explores her career journey, insights, and experiences in HR:
